IN MEDIC, s.r.o.

Running trials

• Active, not recruiting

  A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

  NCT06616194· Phase 3· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Source

• Active, not recruiting

  Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06309966· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Active, not recruiting

  A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

  NCT06315322· Phase 3· Source

• Completed

  A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

  NCT06323928· Phase 2· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

  NCT04666610· Phase 3· Source

• Completed

  Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

  NCT04921384· Phase 3· Source

• Completed

  A Multicenter Open-label Extension Study to Evaluate the Long-term Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures

  2023-506688-32-00· Phase 3· Source

• Completed

  Cenobamate Open-Label Extension Study for YKP3089C025

  NCT03961568· Phase 3· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures

  2023-506687-13-00· Phase 3· Source

• Completed

  Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

  NCT03678753· Phase 3· Source